Qlife Holding AB (QLIFE) AI Stock Analysis

• Market Cap: kr63.35M
• Dividend Yield: N/A
• Average Volume (3M): 97.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: 376.81%
• EPS Growth: 97.95%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.18
• Shares Outstanding: 31,359,041
• 10 Day Avg. Volume: 81,486
• 30 Day Avg. Volume: 97,188
• PEG Ratio: >-0.01
• Price to Book (P/B): -4.74
• Price to Sales (P/S): 109.73
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -126.16
• Revenue Forecast (FY): kr116.00M

• Rating: 44 Neutral
• Price Target: kr2.00 ▼(-33.55% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily weighed down by very weak financial performance, including collapsed revenue, ongoing losses, and continued operating cash burn alongside negative equity. Technicals are more neutral than bearish but do not show strong upside momentum, and valuation remains unattractive/unclear due to losses and no dividend support.

Positive Factors

Deleveraging

Material debt reduction substantially lowers near-term refinancing pressure and interest burden, improving financial flexibility. For a cash-burning biotech, lower nominal debt extends runway and reduces insolvency risk, making follow-on financing or operational restructuring easier to execute.

Proprietary diagnostic platform & revenue model

Owning proprietary diagnostic platforms plus device sales and recurring consumables creates a structural revenue model with recurring aftermarket demand and potential margin tailwinds. Partnerships and research collaborations provide durable channels for product adoption and co-development.

Improving loss and cash outflow trends

Sequential narrowing of losses and reduced operating cash outflows indicate the company is shrinking burn and moving toward cost structure stabilization. Sustained improvement would lower external funding needs and supports longer-term viability if continued across multiple quarters.

Negative Factors

Collapsed revenue

A precipitous drop to a very small revenue base undermines scale economics and product-market fit, making it harder to cover fixed R&D and commercial costs. Persistent minimal revenue limits ability to demonstrate sustainable growth and weakens leverage for partnerships or commercialization.

Negative equity & shrinking asset base

Negative equity and a collapsed asset base materially weaken the balance sheet, increasing going-concern and refinancing risk. With limited tangible assets or equity cushion, the company has less capacity to secure non-dilutive financing and faces higher cost or constraints for strategic investments.

Persistent cash burn

Sustained negative operating cash flow means the business continues to rely on external funding or asset sales to operate. Over the medium term this elevates dilution or debt risk, constrains reinvestment in commercial scale-up, and raises probability of liquidity-driven restructuring if improvements stall.

Qlife Holding AB Business Overview & Revenue Model

Company Description

Qlife Holding AB (QLIFE) is a biotechnology company based in Sweden, specializing in the development of advanced diagnostic tools aimed at improving patient care and health outcomes. The company focuses on innovative solutions in the healthcare sector, particularly in the areas of personalized medicine and point-of-care diagnostics. Qlife's core products include its proprietary diagnostic platforms, which utilize advanced technology to deliver rapid and accurate health assessments.

How the Company Makes Money

QLIFE generates revenue primarily through the sale of its diagnostic products and services. The company offers its proprietary testing platforms to hospitals, clinics, and laboratories, which pay for the devices and associated consumables. Additionally, Qlife may engage in partnerships with healthcare organizations and pharmaceutical companies to develop customized diagnostic solutions, leading to revenue-sharing agreements. The company also explores opportunities in research collaborations and grants, which can provide additional funding and support for its product development initiatives. Continued growth may be driven by expanding its market presence and enhancing product offerings to meet the evolving needs of the healthcare industry.

Qlife Holding AB Financial Statement Overview

Summary

Financial performance is highly stressed: revenue has collapsed (17.99M in 2022 to 0.324M in 2025), profitability remains deeply negative (net income -20.6M in 2025), and operating cash flow is still materially negative (-16.0M in 2025). Debt reduction is a positive, but negative equity (-7.5M in 2025) and a sharply contracted asset base keep overall financial risk elevated.

Income Statement

The income statement is very weak: revenue has collapsed from 17.99M (2022) to 0.324M (2025) with continued negative growth, while losses remain large (net income of -20.6M in 2025 after -56.0M in 2024 and -160.0M in 2023). Profitability is deeply negative (gross profit is negative in recent years, and operating losses persist), indicating the business is not currently covering its cost base. A modest positive is that absolute losses have narrowed materially from 2022–2023 levels, but the scale of revenue is extremely small versus ongoing expenses.

Balance Sheet

The balance sheet shows elevated financial risk due to negative equity in 2023–2025 (equity of -7.5M in 2025), which reduces financial flexibility and raises refinancing/going-concern pressure. Debt has come down significantly from 52.4M (2022) to 8.55M (2025), which is a meaningful improvement, but assets have also contracted sharply (192.7M in 2022 to 9.6M in 2025). Overall, deleveraging helps, but the negative equity position and shrinking asset base keep the balance sheet fragile.

Cash Flow

Cash flow quality is weak: operating cash flow is consistently negative across all years and remains sizable at -16.0M in 2025 (worse than the company’s revenue base), implying ongoing cash burn to fund operations. Free cash flow is also negative in most years (e.g., -54.2M in 2024 and -62.6M in 2023); 2025 shows free cash flow reported as 0, but operating cash flow is still materially negative, so underlying cash generation has not turned. A relative positive is that operating cash outflows have improved versus 2022–2024 peaks, but the company is still reliant on external funding or balance-sheet resources.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	324.00K	50.00K	244.00K	17.99M	39.61M
Gross Profit	-19.38M	-158.00K	-6.31M	-10.75M	44.54M
EBITDA	-18.11M	-12.46M	-150.50M	-78.05M	-35.13M
Net Income	-20.56M	-55.98M	-159.96M	-93.14M	-38.80M
Balance Sheet
Total Assets	9.63M	11.64M	39.05M	192.65M	193.44M
Cash, Cash Equivalents and Short-Term Investments	1.42M	2.71M	1.66M	14.55M	73.46M
Total Debt	8.55M	8.70M	20.25M	52.44M	4.72M
Total Liabilities	17.14M	13.07M	62.17M	101.50M	30.26M
Stockholders Equity	-7.51M	-1.43M	-23.12M	91.15M	132.50M
Cash Flow
Free Cash Flow	0.00	-54.17M	-62.64M	-90.67M	-52.82M
Operating Cash Flow	-15.60M	-37.37M	-41.80M	-47.73M	-26.05M
Investing Cash Flow	0.00	-16.80M	-20.84M	-42.94M	-26.77M
Financing Cash Flow	14.30M	55.23M	49.00M	32.73M	106.02M

Qlife Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Negative. The current price of 3.01 is above the 20-day moving average (MA) of 2.02, above the 50-day MA of 2.12, and above the 200-day MA of 2.70, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.65 is Neutral, neither overbought nor oversold. The STOCH value of 55.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLIFE.

Qlife Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SDOS	50 Neutral	kr58.72M	51.83	―	―	―	―
QLIFE	44 Neutral	kr63.35M	-1.73	437.24%	―	376.81%	97.95%
LXB	44 Neutral	kr48.15M	-2.89	-60.56%	―	163.12%	30.50%
SPEC	43 Neutral	kr53.47M	-1.14	-50.21%	―	―	-108.64%
HEART	43 Neutral	kr134.97M	-1.96	―	―	―	―